Bouzidi Lobna, Makni Saadia, Feki Jihen, Kallel Rim, Graja Soumaya, Gouiaa Naourez, Sellami-Boudawara Tahya, Mellouli Manel
Department of Pathology and Research laboratory LR18SP10, University Hospital Habib Bourguiba, Sfax, Tunisia.
Medical School of Sfax, University of Sfax, Sfax, Tunisia.
Arch Iran Med. 2022 Apr 1;25(4):250-256. doi: 10.34172/aim.2022.41.
Breast cancer represents the most frequent cancer and cause of death in women worldwide and in Tunisia. Cyclin D1 is a gene of cell cycle regulation. It represents a potential oncogene in invasive breast cancer; however; the results are conflicting. We performed a retrospective study aiming to analyze the prognostic impact of cyclin D1 expression in patients with invasive breast carcinoma of no special type and its relation with clinical-pathological features.
One hundred cases of invasive breast carcinoma of no special type diagnosed between 2009 and 2011 were included in this study. Immunohistochemical (IHC) staining was performed for cyclin D1 in all cases. Results were analyzed statistically.
Cyclin D1 positivity was seen in 74 cases (74%), of which 32 cases (32%) showed strong immunoreactivity. Cyclin D1 staining was statistically significantly associated with estrogen receptor (ER) and progesterone receptor (PR) positivity (<0.0001) and with low grade SBR (=0.007). None of the clinical data and other pathological features had any association with cyclin D1 expression (>0.05). Univariate analysis revealed that expression of cyclin D1 was not statistically associated with overall survival (OS) and disease-free survival (DFS) (=0.459 and =0.564, respectively).
These results confirm that cyclin D1 overexpression can be employed as a beneficial prognostic marker and suggest that anti-cyclin D1 therapy may be efficient, especially for ER positive tumors.
乳腺癌是全球及突尼斯女性中最常见的癌症及死亡原因。细胞周期蛋白D1是一种细胞周期调控基因。它是浸润性乳腺癌中的一个潜在癌基因；然而，结果存在争议。我们进行了一项回顾性研究，旨在分析细胞周期蛋白D1表达对非特殊类型浸润性乳腺癌患者的预后影响及其与临床病理特征的关系。
本研究纳入了2009年至2011年间诊断的100例非特殊类型浸润性乳腺癌病例。对所有病例进行细胞周期蛋白D1的免疫组织化学（IHC）染色。对结果进行统计学分析。
74例（74%）病例中可见细胞周期蛋白D1阳性，其中32例（32%）显示强免疫反应性。细胞周期蛋白D1染色与雌激素受体（ER）和孕激素受体（PR）阳性（<0.0001）以及低级别SBR（=0.007）在统计学上显著相关。临床数据和其他病理特征均与细胞周期蛋白D1表达无任何关联（>0.05）。单因素分析显示，细胞周期蛋白D1的表达与总生存期（OS）和无病生存期（DFS）在统计学上无关（分别为=0.459和=0.564）。
这些结果证实细胞周期蛋白D1过表达可作为一种有益的预后标志物，并表明抗细胞周期蛋白D1治疗可能有效，尤其是对于ER阳性肿瘤。
